Home / People / Judith Kok
Portrait ofJudith Kok

Judith Kok

Advocaat

Contact
CMS Derks Star Busmann
Atrium - Parnassusweg 737
1077 DG Amsterdam
PO Box 94700
1090 GS Amsterdam
Netherlands
Languages Dutch, English

Judith Kok is a junior associate in our Life Sciences and Healthcare Sector Group. She advises clients that are active in the field of pharmaceuticals and medical devices on a broad range of legal matters, including advertising and promotion, pricing and reimbursement, clinical research and commercial contracts. ​

Judith also advices on compliance matters related to the Life Sciences industry, often linked to code of conducts and standard operating procedures on anti-corruption and anti-bribery and the industry's self-regulation on its interactions with health care professionals.​

more less

Awards & Rankings

  • The Legal 500 EMEA, 2023, Judith Kok Recommended
more less

Education

  • Master Healthcare Law, University of Amsterdam​
  • Master Civil Law, University of Amsterdam​
  • Bachelor of Law, Utrecht University
more less

Feed

27/03/2024
CMS ranked in the Legal 500 EMEA 2024
The latest rankings of the Legal 500 Europe, Middle East & Africa (EMEA) are out. We would like to thank our clients for their trust in us and their feedback. Our lawyers are described as 'personal...
18/12/2023
CMS advises Carl Zeiss Meditec AG on its acquisition of D.O.R.C.
CMS has advised Carl Zeiss Meditec AG, listed on the MDAX and TecDAX of the German stock exchange and one of the world's leading medical technology companies, on its agreement to acquire all shares in...
18/12/2023
Digital health apps and telemedicine in the Netherlands
Digital Health Apps/Software 1. How is the software within digital health apps classified in your jurisdiction, and what regulation(s) apply? The relevant legislation is the “Wet op de medische hulpmiddelen...
Comparable
12/04/2023
CMS ranked in the new Legal 500 EMEA
The latest rankings of the Legal 500 Europe, Middle East & Africa (EMEA) are out. We would like to thank our clients for their trust in us and their feedback. Our lawyers are described as 'personal, professional...
07/04/2023
CMS advises T&S Groupe on the acquisition of TOPIC
CMS has assisted Technology & Strategy Groupe (T&S), a European leader in engineering and digital consulting, with the acquisition of Topic Ventures B.V. and its 13 subsidiaries. TOPIC is active as an...
15/09/2022
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicines The Medicines Act is the primary law on advertising of medicines. In addition, the Dutch Civil Code...
07/06/2022
Adverse effects of drugs and vaccines The Netherlands
1. Drug adverse effects: kinds of responsibility 1.1 Which are the main kinds of responsibility (contractual, in tort, criminal) of the following subjects with respect to adverse drugs reactions? A...
Comparable
20/03/2020
CMS assists Dutch company with the sale and distribution of approved corona...
There is a great, worldwide need for corona tests. The Dutch CMS Life Sciences & Healthcare Team has assisted a Dutch company with the sale and distribution of approved corona tests under time-critical...
06/09/2019
Blue Tulip Awards - Health
Healthcare Faces Growing Needs Modern-day society is rapidly expanding, putting pressure on our healthcare systems. Therefore, we need to increase the quality of care while reducing costs. Hospitals, practices, laboratories, and corporations will have to step up to keep up with competition, new technology and patients’ growing needs. Innovations in healthcare can provide unique opportunities to transform our society and keep healthcare effective, accessible and affordable to all.  The intellectual property dilemmas caused by AI-generated works With the rise of artificial intelligence (AI) in many sectors, questions pop up about the full extent of AI use and its influence on ownership and ac­count­ab­il­ity. In healthcare, AI is used to support and advise doctors in establishing a diagnosis, assist radiologists in improving image interpretation, and improve drug discovery research, to name just a few of the current ap­plic­a­tions. How­ever, with the rise of a new technologies, new issues arise too. If we take a look at the last example, an important question that comes up is: who owns what when AI does the research? To answer this question - and offer you advice on how to deal with this regarding your AI innovation - we’ll review patent and copyright law in this context. Read more